Fidelity Advisor Biotechnology M holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
Fidelity Advisor Biotechnology Fund - Class M FBTTX
- NAV / 1-Day Return 35.47 / +1.11 %
- Total Assets 1.9B
-
Adj. Expense Ratio
1.210%
- Expense Ratio 1.210%
- Distribution Fee Level Average
- Share Class Type Front Load
- Category Health
- Investment Style Mid Blend
- Min. Initial Investment 0
- Status Open
- TTM Yield 1.19%
- Turnover 51%
USD | NAV as of Jun 13, 2026 | 1-Day Return as of Jun 13, 2026, 5:30 AM GMT+0
Morningstar’s Analysis FBTTX
Will FBTTX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
The People Pillar is our evaluation of the FBTTX management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.
Parent Pillar
The Parent Pillar is our rating of FBTTX’s parent organization’s priorities and whether they’re in line with investors’ interests.
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 48.8
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
AbbVie Inc | 14.83 | 282M | Healthcare |
Alnylam Pharmaceuticals Inc | 5.52 | 105M | Healthcare |
Gilead Sciences Inc | 5.42 | 103M | Healthcare |
Insmed Inc | 3.51 | 67M | Healthcare |
Cogent Biosciences Inc | 3.45 | 66M | Healthcare |
Dianthus Therapeutics Inc | 3.37 | 64M | Healthcare |
Spyre Therapeutics Inc | 3.33 | 63M | Healthcare |
Ascendis Pharma AS | 3.24 | 62M | Healthcare |
argenx SE ADR | 3.17 | 60M | Healthcare |
Biogen Inc | 2.92 | 56M | Healthcare |
United States